56 results about "Oxidized low density lipoprotein" patented technology

The invention relates to a liquid-phase chip kit for acute coronary syndrome and a preparation method for the same. A liquid-phase chip mainly comprises microspheres coated with oxidized low density lipoprotein (ox-LDL), soluble CD40 ligand (sCD40L), matrix metallopeptidase 9 (MMP-9), tissue factor (TF), omentin and endogenous secretory receptor of advanced glycation end products (esRAGE) capture antibody respectively, detection antibodies labelled by biotin, and streptavidin phycoerythrin. The liquid-phase chip provided by the invention has the advantages of being high in detection efficiency, low in the quantity of the needed samples, strong in specificity, high in sensitivity, rapid and accurate in detection, and the like. Simultaneously, the chip reflects a protective factor level and an injury factor level in an organism, so that the risk stratification and prognosis conditions of a patient can be much comprehensively assessed. Simultaneously, the preparation method disclosed by the invention is simple and practicable, and good in stability, various process parameters such as the quantities of the microspheres and the antibodies, and the reaction process in the technical scheme of the preparation method are obtained on the basis of lots of experiments, and are the optimal parameter values of the preparation process.

The invention provides an enzyme-linked immunosorbent assay (ELISA) kit for human oxidized low-density lipoprotein, which comprises the following ingredients: (1) an ELISA plate coated with an anti-human oxidized low-density lipoprotein antibody; (2) serial standard solution of human oxidized low-density lipoprotein; (3) an enzyme-labeled antibody; (4) diluting solution; (5) washing solution; (6) substrate solution; and (7) stopping solution. The invention further provides a method for using the kit and application of the kit. Compared with the traditional detection means for coronary heart disease, the kit has the characteristics of no wound, good simplicity, convenience and rapidness, high sensitivity and low cost.

The present invention provides a method of preventing or treating a disease caused by oxidation in vivo by administering a pharmacologically effective amount of at least one compound selected from the group consisting of: (1) 2,5,7.8-tetramethyl-2-(beta-carboxyethyl)-6-hydroxychromane; and (2) 2,7.8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychromane. Further, it provides use of a compound selected from the group consisting of (3) a-tocopherol, (4) a-tocotrienol, (5) gamma-tocopherol and (6) gamma-tocotrienol for generation in vivo of any of the above compounds (1) and (2) to treat a disease caused by oxidated low density lipoprotein (LDL). As the above-mentioned disease, arteriosclerosis is particularly preferred.

The invention discloses a preparation method and application of cordyceps militaris sporocarp heteropolysaccharide. The preparation method mainly comprises the following steps that cordyceps militaris sporocarp is subjected to drying, pulverization, ethanol degreasing and hot water ultrasonic extraction, and an extracting solution is subjected to concentration, alcohol precipitation, deproteinization, column chromatography, dialysis and freeze-drying, so that the cordyceps militaris sporocarp heteropolysaccharide TY258 is obtained. The cordyceps militaris polysaccharide has the efficacy of lowering lipid and resisting to atherosclerosis and can remarkably lower the cholesterol level, the triglyceride level and the low density lipoprotein level of high-fat induced atherosclerosis model mice (mice with apolipoprotein and low density lipoprotein receptors knocked out) and lipid accumulation of the livers and arcus aortae at the concentration of 25 mg/kg, lift the high density lipoprotein cholesterol level of the mice and improve activity of superoxide dismutase and lipoprotein esterolysis enzyme. The cordyceps militaris sporocarp polysaccharide can also remarkably lower the contents of plasma triglyceride, cholesterol, malonaldehyde and oxidized low-density lipoprotein of high-fat induced guinea pigs and rats.

The present invention provides an indirect competition method for golden test paper for detecting micro-oxidation low density lipoprotein colloid. The competition method is applied to the test paper. A certain amount of golden dot antibody is covered on the golden dot antibody pad. The oxidation low density lipoprotein is covered on a detecting region. Through the observation of the color of the detecting region, whether the oxidation low density lipoprotein in the serum or the plasma of a human body being higher than a normal level can be detected. The present invention is convenient and quick; the detection of the oxidation low density lipoprotein can be directly carried out; and the present invention provides reliable evidence to the early diagnose of atherosclerosis.

The invention discloses a composition for treating atherosclerosis. The composition is characterized by comprising geranialdehyde used as an effective component, wherein the geranialdehyde is from lemon myrtle, litsea cubeba, cubeb litsea tree, lemon grass and lemon tea tree, wherein the concentration of the geranialdehyde is 1-51g/ml. The pharmaceutical composition containing the geranialdehyde has an unequal inhibition effect on hyperplasia of human aortic smooth muscle cells stimulated by lipopolysaccharide. Compared with the geranialdehyde and other flavonoid compounds, the composition has the best activity, can inhibit hyperplasia of human aortic smooth muscle cells caused by oxidized low-density lipoprotein, does not have toxicity on cells, and can inhibit inflammatory response.

Provided is a monoclonal antibody against slightly oxidized LDL, which can play a role as an important tool in the research and development of oxidized LDL. Also provided are a kit for the simple detection of slightly oxidized LDL and a method for the simple detection of slightly oxidized LDL from the biological sample of a subject to be tested which use the monoclonal antibody. By means of ELISA (Enzyme-Linked Immunosorbent Assay) using the monoclonal antibody as the solid phase antibody and an anti-apolipoprotein B antibody as the detection antibody, the degree of reaction between a severely oxidized low-density lipoprotein and the monoclonal antibody is low in comparison to the degree of reaction between a slightly oxidized low-density lipoprotein and the monoclonal antibody, and the monoclonal antibody specifically reacts with an oxidized low-density lipoprotein.

The present invention provides a piece of semiquantitative detecting oxide low-density lipoprotein (OX-LDL) colloid selenium reagent paper, which can capture antigen quantity according to OX-LDL monoclonal antibody to create a relation between color and standard OX-LDL and diagnose that content of OX-LDL in human blood plasma is higher than, lower that or equal to standard OX-LDL quantity in human blood plasma, thus realizing early auxiliary diagnosis to ASCVD. The present invention has the advantages of convenience, quickness, sensitivity, specificity and economic efficiency, rejects specified instruments and equipments and is conveniently taken.

The invention belongs to the technical field of biomedicine, in particular to a natural anti-oxidation low-density lipoprotein (oxLDL) IgM subclass antibody for suppressing atherosclerosis. The natural anti-oxidation low-density lipoprotein (oxLDL) IgM subclass antibody is characterized in that a Babl/c rat is bred with a high-cholesterol diet for 4 weeks under a condition of no special pathogen;splenic cells (B cells primarily) are separated, the B cells and myeloma cells are combined by a chemical method, and hybridoma cells are obtained; and oxidized low-density lipoprotein (oxLDL) is usedas an antigen, an indirect enzyme-linked immunosorbent assay (ELISA) experiment is carried out on the growth holes of the positive hybridoma cells, positive cloning holes are determined, and the required cloning positive cells are screened out by a limiting dilution method. The obtained cloning positive cells are cloned and multiplied, cells generating a monoclonal antibody are obtained, and thenatural oxLDL-resisting immunoglobulin M (IgM) subclass antibody 3A6 is obtained. The antibody can be used for lowering the formation of the atherosclerosis of the rat and provides a novel idea and anovel method for researching the generation, the development and the treatment of the atherosclerosis.

The invention discloses the use of anthocyanin in medicines for treating atherosclerosis and the application for preventing and treating atherosclerosis with regulation and control of CHOP gene, and relates to the improvement effect of anthocyanin monomer cyanidin-3, 5-diglucoside on macrophage injuries caused by oxidized low density lipoprotein, and discusses the mechanism of action thereof. In the invention, mouse macrophage cell line RAW264.7 is tested, and the effect of cyanidin-3, 5-diglucoside on activity of RAW264.7 macrophage processed by the oxidized low density lipoprotein is determined based on MTT method, the total RNA of cells is extracted, Affymetrix Mouse U4302.0 gene expression profile chip is applied to carry out marking hybridization experiments, differential gene analysis is carried out for the scanning results of Affyemtrix gene chip with MTT method, and the differential genes are screened, and further real-time quantitative PRC method is utilized to further validate the expressed differential gene, The validation results verify that the cyanidin-3, 5-diglucoside can regulate CHOP gene expression down, and has obvious protective action on macrophages injured by oxidized low density lipoprotein.

The present invention relates to the use of Heat Shock Proteins and fragments thereof as targeting ligand. The Heat Shock Protein may be labeled with imaging agents that are capable of binding lectin-like oxidized low-density lipoprotein (LOX-1) or may be attached to a therapeutic agent. The sequences are useful for the diagnosis and monitoring of diseases as well as means for internalizing signaling moieties and therapeutics.

The application of the invention belongs to the technical field of biosensors, and specifically discloses preparation method of a biomolecule terahertz sensor chip of a universal nano-scale fluid andits use in liquid-phase sensing of biological macromolecules, and the preparation method comprises the following steps of (1) making silicon wafers into SRRs metamaterials for future use; (2) selecting silicon wafers, and manufacturing PDMS channels on the silicon wafers; (3) bonding the SRRs metamaterials in the step (1) and the PDMS channels in the step (2) to prepare a terahertz sensor chip; (4) detecting a variety of highly absorbent liquids; and (5) detecting oxidized low-density lipoprotein at different concentrations. The invention is mainly used for preparing the terahertz sensor chipand performing sensing of a superabsorbent solution by using the terahertz sensor chip, solves the big difficulty of sensing high-absorbent liquids in the terahertz field, has low detection sensitivity, and realizes the detection of biological macromolecules in a liquid phase environment.

The invention belongs to the field of medical detection, particularly relates to an enzyme linked immunosorbent assay kit used for detecting human ox-LDL (oxidized low-density lipoprotein). The linked immunosorbent assay kit comprises components as follows: (1), an elisa plate coated with human ox-LDL antibodies; (2), standard products in human ox-LDL series; (3), an enzyme-labeled antibody solution; (4), a diluent; (5), a washing liquid; (6), a substrate solution; (7), a developing solution; (8), a stop solution.

The invention discloses a method for chemiluminiscence imaging immunoassay method for simultaneously measuring oxidized lipoproteins (a) and low-density oxidized lipoproteins of human serum. According to an analysis system, a multi-component immunosensor modified by silanization is used as a solid-phase carrier; a solid-phase antibody is prepared by covering the carrier with a capturing antibody; a sample to be measured or a standard series solution is added into the solid-phase antibody; after the solid-phase antibody and the sample to be measured or the standard series solution fully react, an antibody labeled with horse radish peroxidase is added to form a sandwich immune compound; finally a chemiluminescence substrate, namely luminal-hydrogen peroxide, is added for reaction; the luminous intensity is detected through a high-resolution charge coupler, so that the oxidized lipoproteins (a) and the low-density oxidized lipoproteins of the human serum can be measured simultaneously, and the immune reaction condition, the enzyme conjugate dilution degree, the detection time and the like are optimized; furthermore, the indexes such as linear range, precision, accuracy and detection limit of the method are checked. The analysis method has the advantages of simplicity in operation, high sensitivity, narrow linear range, high stability and the like and has a certain clinical application value.

The invention provides application of oxidized low density lipoprotein for inducing mesenchymal stem cells to differentiate to myocardium-like cells. The experiment shows that when oxidized low density lipoprotein with concentration of 5 micrograms/mL is added into a culture medium of mesenchymal stem cells, BMMSCs have remarkable cell proliferation, the expression of myocardium-like cell specific protein and myocardium cell indicative molecules can be detected, which means that the mesenchymal stem cells are directionally differentiated to myocardium-like cells, and the conversion rate of the myocardium-like cells is as high as 30%.

The invention discloses an efficient soluble expression and purification method of human LOX-1 (lectin like oxidized low density lipoprotein receptor-1) extracellular domain, and relates to construction of an expression vector for efficient soluble expression of human LOX-1 extracellular domain (hLOX-1ECD) in E.coli, establishment of conditions for the efficient soluble expression and establishment of large-scale large amount purification process. The efficient soluble expression and purification method can be used for preparing large amount of hLOX-1ECD. According to the efficient soluble expression and purification method of human LOX-1 extracellular domain, the purification process is simple, convenient and feasible, a large amount preparation can be realized, and the purified hLOX-1ECD protein has high purity.

The invention belongs to the technical field of medical models, and discloses an animal heart failure model and a construction method thereof. The construction method of the animal heart failure modelcomprises the following steps: obtaining an 8-week-old SPF-grade male C57/BL6 mouse, putting the mouse into a purification cage, controlling the temperature at 19-23 DEG C and the relative humidity at 40-50%, keeping bright illumination and dark illumination, each for 12 h, feeding the mouse with a standard mouse feed, and allowing freely drinking of water so as to carry out adaptive feeding; after 1 week of the adaptive feeding, implanting the mouse with a microosmotic pump containing oxidized low density lipoprotein, and waiting for 4 weeks so as to obtain the animal heart failure model; and then, determining degree of heart failure by adopting echocardiography, plasma BNP level and the like. Different from previous heart failure models induced by pressure load, volume load, myocardialischemia and cardiotoxic drugs, the animal heart failure model prepared by the construction method fills in the blank of animal models with heart failure of unknown causes, and pertains to novel animal heart failure models with the heart failure caused by hyperlipidemia. The animal heart failure model is good in repeatability, simple, and objective.

The invention relates to a preparation method of low-density lipoprotein, in particular to a preparation method of oxidized low-density lipoprotein and application thereof, belonging to the technical field of the medical test. Through extraction and identification of the oxidized low-density lipoprotein and research on promoting myocardial fibrosis of the oxidized low-density lipoprotein in vitro, the method utilizes the effect of the extracted oxidized low-density lipoprotein on the myocardial fibrosis to investigate the occurrence mechanism of the myocardial fibrosis and can promote the research and development of the drug against the myocardial fibrosis through blocking the signal pathway.

Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).

The invention belongs to the field of biochemical engineering, and in particular relates to a chemical synthetic method of a low affinity ligand of an oxidized low density lipoprotein receptor CD36. The method comprises the following steps of: carrying out a chemical reaction on 4-Dimethylaminopyridine, N, N'-Dicyclohexylcarbodiimide, azelaic acid and 7-ketocholesterol; and obtaining oxLig-1 through extraction, sample mixing, packing, purification and collection. Experiments show that the chemically synthesized oxLig-1 has same physiological activity with that of oxLig-1 separated and purified from oxLDL (oxidized low density lipoprotein), and the oxLig-1 activates cell signaling mediated by CD36. According to the chemical synthetic method disclosed by the invention, oxLig-1 is synthesized by the chemical method, and oxLig-1 has a completely consistent chemical structure with that of the low affinity ligand of CD36 and can activate ERK (Extracellular Signal-Regulated Kinase) and JNK (Jun N-Terminal Kinase) and up-regulate expression of a cholesterol outflow gene, namely, a triphosadenine binding cassette transporter A1 (ABCA1).

An active substance of medication or health product for hyperlipidemia and hypercholesterolemia comprises djulis, and which can effectively inhibit the absorption of cholesterol, advance the metabolism of cholesterol, promote the anti-oxidation and decrease the accumulation of oxidized low-density lipoprotein-cholesterol in vessel walls of organisms.